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Abstract
Regulation of bone homeostasis depends on the concerted actions of bone-forming osteoblasts and 
bone-resorbing osteoclasts, controlled by osteocytes, cells derived from osteoblasts surrounded by 
bone matrix. The control of differentiation, viability and function of bone cells relies on the 
presence of connexins. Connexin43 regulates the expression of genes required for osteoblast and 
osteoclast differentiation directly or by changing the levels of osteocytic genes, and connexin45 
may oppose connexin43 actions in osteoblastic cells. Connexin37 is required for osteoclast 
differentiation and its deletion results in increased bone mass. Less is known on the role of 
connexins in cartilage, ligaments and tendons. Connexin43, connexin45, connexin32, connexin46 
and connexin29 are expressed in chondrocytes, while connexin43 and connexin32 are expressed in 
ligaments and tendons. Similarly, although the expression of pannexin1, pannexin2 and pannexin3 
has been demonstrated in bone and cartilage cells, their function in these tissues is not fully 
understood.
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1. Introduction
Musculoskeletal systems are faced with a plethora mechanical and systemic signals that 
require tightly organized cell responses to occur in order to maintain structural and 
functional integrity [1]. Coordinated cellular responses to these extracellular cues can occur 
directly or indirectly through communicative channels, including gap junctions, connexin 
hemichannels and/or pannexins channels. For example, in bone, osteoblasts and osteocytes 
form an extensive interconnected network, which express robust amounts of connexin43 
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(Cx43), as well as other connexins and pannexins [2,3]. This osteogenic network, 
interconnected by Cx43 in particular, is vital to how bone responds to mechanical load and 
mechanical unloading stimuli, as well as how bone responds to hormonal and growth factor 
cues to regulate bone quality [4,5]. In other musculoskeletal tissues like tendon, ligaments 
and cartilage, it is less clear how the cells that compose these systems use connexins and 
pannexins to regulate function. Yet, as it will be discussed below, growing evidence 
demonstrates a substantial contribution of these communicative channels to the optimal 
function of these cells. This review will focus on the presence and roles of connexins and 
pannexins in osteoblasts/osteocytes, osteoclasts, tenocytes, chondrocytes and ligamentous 
fibroblasts.
Bone homeostasis is controlled by the coordinated actions of osteoblasts, the bone-forming 
cells, and osteoclasts, the bone-resorbing cells [4]. Osteocytes, cells derived from osteoblasts 
that became enclosed by bone matrix, are thought to be the main regulators of the 
differentiation and function of osteoblasts and osteoclasts. Osteoblasts originate from 
osteochondroprogenitors, the same cells that give origin to chondrocytes, and their 
differentiation occurs through changes in gene expression that can be affected by changes in 
connexin levels. The function and viability of osteocytes are also affected by connexins. 
Osteoblast and osteocytes control osteoclast differentiation by producing the pro-
osteoclastogenic cytokine receptor activator of nuclear factor kappa-B ligand (RANKL) and 
the anti-osteoclastogenic cytokine osteoprotegerin (OPG) [6]. The ratio between these 2 
molecules dictates osteoclast differentiation, and, as will be detailed below, is highly 
regulated by Cx43 expression. Furthermore, connexins also affect osteoclast differentiation 
directly. In cartilage, tendon and ligament, the role of connexins and pannexins are only just 
beginning to come into focus. The data that are coming in suggest that there are some 
conserved pathways among cells of the skeletal systems by which connexins and pannexins 
may regulate cell signaling, differentiation, and function.
2. Expression of connexins and pannexins at tissue and cellular level
2.1. Connexins: gap junctions and hemichannels
Connexins permit the rapid dissemination of shared molecules and ions among cells of the 
musculoskeletal system via cell-to-cell communication. Connexins can link cells directly in 
the form of classic gap junction channels in which hexamers of connexins assemble a pore 
structure in the plasma membrane of one cell and then docks with a connexin pore on an 
adjacent cell, forming a continuous, aqueous channel between the 2 cells. Small molecules 
roughly 1kDa or less can diffuse through these channels, permitting cells to directly and 
efficiently share signal molecules, ions and other low molecular weight molecules [7]. Gap 
junctions facilitate both electrical and chemical (i.e. second messenger) coupling [8]. In 
addition, numerous factors, including posttranslational modifications, dynamically regulate 
the open/closed state of the gap junction channel and the abundance of connexins influence 
downstream signaling as well. Therefore, connexins and gap junctions are more than passive 
channels that link cells together. Recent data have suggested that connexins can pass larger 
biomolecules, including nucleic acids, suggesting another level of functional coupling of 
cells [9,10]. In addition to classic gap junction channels, unopposed connexin pores, also 
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known as hemichannels, can function to exchange small molecules between the intracellular 
space and the extracellular fluid. As will be discussed in more depth below, this function 
may explain the expression of connexins in tissues with limited cell-to-cell contact. There 
are 21 connexin genes [7]. Most tissues express 1 or more of the genes. Cx43 (gene name 
Gja1) is the most abundant and most heavily studied gap junction protein expressed by 
skeletal cells. Additionally, Cx45 (gene name Gjc1), Cx46 (gene name Gja3) and Cx37 
(gene name Gja4) have also been described in skeletal system and, as will be discussed in 
greater detail, their contribution to tissue function is emerging.
2.2. Connexins in bone
Cx43 is the most highly expressed connexin in all bone cell types, including osteocytes, 
osteoblasts and osteoclasts [11–14]. Cx45 and Cx46 expression has been detected in 
osteoblastic cells [2,15,16] and in recent studies, the expression of Cx37 has been 
demonstrated in osteoblasts, osteocytes and osteoclasts [17,18]. The gap junctional coupling 
of bone cells results in the formation of an elaborately interconnected functional syncytium 
among the bone-embedded osteocytes and bone progenitors and osteoblasts on bone 
surfaces.
2.3. Connexins in other skeletal tissues
Cartilage is a specialized but flexible connective tissue made up of collagen fibers and 
proteoglycans that are secreted by chondrocytes. Donahue and colleagues reported the 
expression of Cx43 and the presence of functional gap junction channels in chondrocytes 
isolated from bovine articular cartilage [19]. Further studies demonstrated that, in addition to 
high levels of Cx43, human chondrocytes express Cx45, Cx32 and Cx46 [20]. In addition, 
using an animal model in which the Cx29 gene was replaced by LacZ, it was recently shown 
that this connexin is expressed in chondrocytes of the fibrous cartilage of the intercalated 
discs and in the epiphysis of the vertebrae [21].
Ligaments are composed of fibrous tissue connecting bones or cartilages, serving to support 
and strengthen joints. Expression of Cx43 [22,23] as well as of Cx32 [24], Cx40 and Cx45 
[25] was found in cells from periodontal ligaments. Cx43 expression and the presence of gap 
junctions has also been detected in medial collateral ligaments [26]. Of note, the localization 
of Cx43 staining differs in isolated ligament cells in vitro from that of intact ligaments.
In tendons, a fibrous tissue synthesized by tenocytes that attaches muscle fibers to bone or 
cartilage, microscopy studies showed the presence of Cx43 in cell processes and of Cx32 in 
cell bodies of cells from rat flexor tendon [27]. The same 2 connexins are expressed in 
equine [28], avian [29] and sheep [30] tendon. The 2 connexins exhibit distinct localization, 
with Cx43 found in the tip of the cell processes as well as between cell bodies and Cx32 
only between cell bodies [27].
2.4. Pannexins in bone, cartilage, ligament and tendon
There are 3 pannexins genes, namely Panx1, Panx2, and Panx3, which encode proteins with 
strikingly similar structural topology to connexins. Despite their structural similarities, 
pannexins have little sequence homology with connexins and function exclusively as an 
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unpaired channel, thereby communicating signals, primarily adenosine triphosphate (ATP), 
directly between the cytoplasm and the extracellular space [31,32]. Panx1 and Panx3 are 
broadly expressed, including in skeletal cells [33,34]. Panx1 is found in murine osteoblastic 
cells [35], whereas Panx3 is expressed in various osteoblastic cell lines and primary calvaria 
cells and in hypertrophic chondrocytes [36–39]. Panx2 was thought to exhibit a more 
restricted expression, being most abundant in the brain, spinal cord and neurons [40–42]. 
However, recent studies showed that Panx2 has a wider expression pattern [43] and can be 
detected in osteoblastic cells [36]. Panx1 expression was also found in periodontal ligaments 
[44], while there are no reports of pannexin expression in tendons.
3. Connexins in bone
3.1. In vitro studies
In vitro gain-of-function and loss-of-function studies have made clear that Cx43 controls 
osteoblast and osteocyte function and influences cell survival. Early studies demonstrated 
that the relative abundance of Cx43 in cells of the osteoblast lineage impacted their ability to 
differentiate, with increased coupling via Cx43 promoting osteoblast differentiation and 
function and inhibition of Cx43 reducing osteoblast differentiation and function [45–48]. In 
Cx43 knockout models, there is a cell autonomous dysfunction in the osteoblast lineage, 
including reduced expression of markers of osteoblast differentiation [49–54]. Cx43 
regulates osteoblastogenesis and cell survival, not only by the passive exchange of second 
messengers between cells, but also by actively modulating signal transduction cascades. 
Increasing Cx43 levels in osteoblasts or osteocytes increases extracellular signal-regulated 
kinase (ERK) signaling [55–57]. This activation of ERK by Cx43 is caused by cell-to-cell 
communication of signals, as direct cell-to-cell contact is required for this effect, and the 
percentage of cells that become ERK-positive in response to a specific cue is increased 
when Cx43 is overexpressed [58]. Similarly, Cx43 gain-of-function increases protein kinase 
C delta (PKCδ) activation by fibroblast growth factor 2 (FGF2) in cultured osteoblasts 
[58,59]. Cx43 also alters protein kinase A-dependent signaling by sequestering β-arrestin in 
osteoblasts stimulated with parathyroid hormone (PTH) [60]. In fact, such interactions may 
represent a fundamental way that Cx43 influences signaling cascades. β-arrestin forms a 
complex with the Cx43 C-terminal domain in PTH-treated osteoblasts. This interaction with 
Cx43 prevents β-arrestin from blunting cyclic adenosine monophosphate (cAMP)-dependent 
signaling from the PTH receptor, leading to enhanced cell survival. Furthermore, deletion of 
Cx43 or removal of the C-terminal domain prevents the sequestration of β-arrestin by Cx43 
and abolished the ability of PTH to promote osteoblast survival. Similarly, the Cx43 C-
terminus is required for ERK activation resulting in cell survival [60]. In addition, PKCδ 
was shown to physically bind to the Cx43 C-terminal domain [61] and interactions with the 
C-terminus are required for Cx43 overexpression to enhance osteoblast signaling and gene 
expression following FGF2 administration [62]. Another example of this structure-function 
relationship between the C-terminal domain of Cx43 and signaling cascades in cells of the 
osteoblast lineage is the interaction of Cx43 with α5β1 integrin in osteocytes [63,64]. In 
vitro studies show that the interaction between Cx43 and α5 integrin permits the opening of 
Cx43-based hemichannels in response to fluid flow sheer stress. Once opened, these 
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osteocyte Cx43-based hemichannels have been implicated in the release of autocrine/
paracrine effectors, including ATP and prostaglandin E2 [65–67].
Cx43 can modulate osteoblast/osteocyte function by regulating numerous effectors. 
Increasing or decreasing Cx43 expression or function in osteoblast cell lines alters 
specificity protein 1 (Sp1) recruitment to osteoblast promoters, leading to changes in gene 
expression [68,69]. This effect is mediated downstream of ERK activation with Cx43 
supporting robust ERK activity and concomitant Sp1 recruitment, while disruption of Cx43 
function attenuates ERK activation leading to diminished Sp1 recruitment [56]. Indeed, the 
modulation of an ERK/Sp1 axis by Cx43 has been shown in other cell systems, suggesting 
functional conservation [70–72]. In bone cells, this Cx43-dependent recruitment of Sp1 can 
also enhance the recruitment and transcriptional activity of specific protein 7 (Sp7)/Osterix, 
a master regulator of osteoblastogenesis, to osteoblast promoters [68] Similarly, Cx43-
dependent ERK activation promotes cell survival signals downstream of bisphosphonates 
[55,57]. Cx43 can also effect signaling through an inositol polyphosphate/PKCδ cascade to 
influence another master regulator of osteoblastogenesis, Runt-related transcription factor 2 
(Runx2) [58,59,73]. In addition, loss of Cx43 reduces the bone morphometric protein 2 
(BMP2)-responsiveness of osteoblasts [74].
Overall, these Cx43-influenced signals impact the expression of osteoblast genes involved in 
the control of differentiation (i.e. Runx2 and Sp7/Osterix), matrix production (i.e. collage 
type 1-alpha 1 chain (Col1a1), gamma-carboxyglutamic acid-containing protein (Bglap)/
osteocalcin) collagen processing and crosslinking (i.e. lysyl oxidase), osteoclastogenic 
factors (i.e. OPG and the RANKL/OPG ratio) and sclerostin [45,51–53,62,75–78]. Notably 
in most of these examples, increasing Cx43 production enhances signaling and the 
expression of osteoblast genes, while decreasing Cx43 attenuates osteoblast differentiation. 
However, in vivo experiments on the role of Cx43 in bone have shown that context matters. 
For example, during mechanical loading, loss of Cx43 increases the anabolic response of 
bone, whereas during mechanical unloading, Cx43 deletion can diminish bone loss and even 
in this context this view is somewhat oversimplified, as these responses can differ in 
periosteal osteoblasts and endosteal osteoblasts [52,78–81]. A few in vitro studies highlight 
the context dependence of the role of Cx43 in osteoblast/osteocyte function. Loss of Cx43 
has been shown to reduce the inhibitory effects of endothelin-1 on osteoblasts [82,83], 
perhaps by disrupting calcium-dependent signaling events [84]. Similarly, loss of Cx43 
increases β-catenin levels in cultured osteocytes, enhancing their mechano-responsiveness 
[85].
Interestingly, mounting in vitro and in vivo evidence demonstrates that heterogeneous cell-
to-cell coupling can influence bone cell function, with osteocytes [86–88], fibroblasts [89], 
endothelial cells [90–93] and megakaryocytes [90] influencing osteoblast function when 
interconnected by Cx43-containing gap junctions. In addition, osteoblastic Cx43 expression 
has been shown to contribute to the maintenance of the hematopoietic niche [94] and to even 
indirectly regulate skeletal muscle function [95].
Beyond the indirect control of osteoclasts by the osteoblast/osteocyte RANKL/OPG/Cx43 
axis, little is known about the direct role of connexins in bone-resorbing osteoclasts. 
Plotkin and Stains Page 5
Cell Mol Life Sci. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Osteoclasts also express Cx43 [96]. Blocking of Cx43 in human and rodent osteoclasts in 
vitro can impact osteoclast fusion and function in vitro [96–98]. Furthermore, strong 
expression of Cx43 is observed in the giant osteoblasts found in patients with Paget’s 
disease and giant cell tumors of bone, suggesting a role for Cx43 in the formation of these 
cells [97]. In contrast, a clear role for Cx37 in osteoclastogenesis has been shown [17]. 
Osteoclasts derived from Cx37 knockout mice are smaller, with fewer nuclei and exhibit 
markedly reduced expression of a host of osteoclast markers as well as increased Notch 
signaling.
3.2. In vivo studies
Genetically modified mouse models—Mice with global deletion of Cx43, which 
results in perinatal death, exhibit delayed ossification due to dysfunction of osteoblastic cells 
[16,49]. Mice with deletion of Cx43 in cells of the osteoblastic lineage are viable and exhibit 
a bone phenotype that is progressively more profound, as the cells in which the connexin is 
deleted are less differentiated [51,75,78,99]. Thus, deletion of Cx43 from 
osteochondroprogenitors using the Dermo1/Twist2 promoter to target Cre recombinase 
expression leads to decreased bone mass and reduced length of long bones [51]. Deletion in 
committed osteoblast progenitors using Cre recombinase under the control of the 2.3kb 
fragment of the collagen 1a1 gene also results in reduced bone mineral density [75], but 
mice are not shorter than their littermates expressing Cx43 [95]. This suggests that Cx43 
expression in osteochondroprogenitors, but not in committed osteoblasts, is required for 
normal long bone growth. Deletion of Cx43 from mature osteoblasts, using the human 
osteocalcin promoter to drive Cre expression, or from osteocytes only, using the 8kb 
fragment of the dentin matrix protein 1 promoter, does not affect either bone mineral density 
or longitudinal growth [52,53,99].
A recent study shows that deletion of Cx43 from osteoblast progenitors using the osterix-Cre 
mice results in delayed intramembranous ossification [74]. However, it has been shown that 
mice expressing the osterix-Cre show a defect in craniofacial bone development even in the 
absence of any floxed gene [100] and, therefore, the presence of Cre under the control of the 
osterix promoter might contribute to the intramembranous ossification defect. Nevertheless, 
mice with Cx43 deletion in osterix-expressing cells exhibit a similar cortical bone phenotype 
[74] as other mice with bone cell-specific Cx43 deletion, as will be detailed below.
Further support for a role of Cx43 in osteoblast differentiation was provided by studies in 
which microRNA 206 (miR-206) was overexpressed under the control of the 2.3 kb 
fragment of the collagen1a1 promoter [101]. These animals exhibit decreased mass of 
trabecular and cortical bone and low levels of Cx43. In addition, in vitro experiments 
showed that the decrease in alkaline phosphatase induced by miR-206 expression is reversed 
by transfection with Cx43, which is a target of miR-206. While the decrease in Cx43 protein 
levels might be responsible in part for the phenotype of miR-206 transgenic mice, other 
genes are involved, because the phenotype of miR-206 transgenic mice is more profound 
than those in which Cx43 was deleted using the same promoter [75].
Despite the difference in bone mass and size, all animal models of Cx43 deletion in cells of 
the osteoblastic lineage exhibit increased periosteal bone formation and endocortical bone 
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resorption, resulting in widening of the marrow cavity and the external perimeter of long 
bones, albeit the effect is more profound when the connexin is deleted earlier in the 
osteoblastic lineage [51,53,74,78,79]. These mice display increased cortical osteocyte 
apoptosis [52,53,99], periosteal bone formation and a high RANKL/OPG ratio, which favors 
osteoclast differentiation [51,53,78], resulting in increased bone resorption. Loss of 
osteocytic Cx43 reproduces many of the features of Cx43 deletion in cortical bone [53], 
suggesting a fundamental role of osteocytes in the gap junction network. However, the 
increasing severity of the skeletal phenotype in models were Cx43 is deleted in less mature 
osteoblastic cells implies that Cx43 plays a role in osteoblast function as well. In addition to 
its role in bone mass and cortical bone structure, osteocytic Cx43 might play a role in 
regulating intracortical bone resorption and the removal of surrounding bone matrix by 
osteocytes, a process known as osteocytic osteolysis [5], as suggested by the increased 
osteocytic lacunar size in mice lacking Cx43 in osteoblasts and osteocytes [102].
Mutations in the Cx43 gene associated with oculodentodigital dysplasia (ODDD) [103] and 
craniometaphyseal dysplasia [104] result in skeletal manifestations in humans. These 
abnormalities have been reproduced in 2 animal models in which mutated Cx43 genes (i.e. 
G138R and G60S) are expressed in all cells and tissues [105–107]. In addition, expression 
the G138R-Cx43 in osteochondroprogenitors recapitulates the skeletal phenotype of mice 
with global expression of the mutated gene [51]. Recent studies showed that, besides the 
decreased bone mass, mice expressing G60S-Cx43, a dominant-negative mutant that 
disrupts gap junction assembly and function, exhibit changes in the bone marrow with 
progressive bone marrow atrophy and increased adipocytes [107,108]. These phenotypic 
changes were not reported for mice carrying the G138R-Cx43 ODDD mutation, which does 
not alter gap junction assembly, but that forms communication-deficient gap junction 
plaques [105] or in any of the mouse models of bone-specific deletion of Cx43. The 
mechanism by which mutated G60S Cx43 increases adipogenesis remains to be determined.
Recent evidence shows that Cx43 expression in osteoblastic cells not only controls bone 
mass and structure, but also skeletal muscle growth and function [95]. Thus, mice in which 
Cx43 was deleted using the 2.3kb fragment of the Col1a1 promoter to target Cre expression 
exhibit lower weight and strength of fast twitching muscles than littermates controls 
expressing Cx43. These effects of osteoblastic Cx43 have been linked to a decrease in 
undercarboxylated glu-osteocalcin. Indeed, glu-osteocalcin promotes myotube formation in 
vitro and rescues the effect of Cx43 deletion on muscle mass and strength in vivo. The 
decrease in muscle mass is associated with reduced body weight without changes in body 
size. On the other hand, mice lacking Cx43 in mature osteoblasts or in osteocytes do not 
exhibit reduced body weight [52,53,99], suggesting that the regulation of muscle 
development by Cx43 is restricted to its expression in immature osteoblasts.
In addition to the regulation of osteoclast differentiation through Cx43 expression in 
osteoblasts and osteocytes [51,53,78], the gap junction protein is also required for osteoclast 
differentiation in a cell-autonomous manner. This was reported recently in a study in which 
Cx43 was deleted using the human cathepsin K promoter to target Cre expression to pre-
osteoclasts [109]. These mice exhibit fewer osteoclasts on the trabecular bone of the distal 
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femur and increased cortical thickness and reduced trabecular spacing, suggesting reduced 
osteoclastic bone resorption [109].
As in mice, deletion of Cx43 in other vertebrates also results in a bone phenotype, with limb 
[110,111] and face [112] abnormalities in chicken. Like in mice, complete deletion of Cx43 
in zebrafish is lethal, but mutation of Cx43 results in the so-called short-fin phenotype, with 
short bony segments and reduced cell proliferation in the fin skeleton [113]. Recent studies 
showed that hyaluronan and proteoglycan link protein 1a (Hapln1a) and semaphorin3d both 
work downstream of Cx43 to regulate cell proliferation and joint formation in zebrafish fin 
bones [114].
Bone-acting stimuli and Cx43 in bone cells—Cx43 not only is required for bone 
development and structure under basal (i.e. non-stimulated) conditions, as evidenced by the 
genetic manipulations, but also for the response of the skeleton to bone-acting stimuli. In 
particular, the bone-protecting bisphosphonate drugs [115] preserve osteoblast and osteocyte 
viability by opening Cx43-based hemichannels [116,117] and the survival effect of the drugs 
is abolished in mice lacking Cx43 in osteocytes [99]. Intermittent administration of PTH is 
the only Food and Drug Administration (FDA)-approved treatment to increase bone mass 
[118]. Cx43 expression appears to be required to obtain a full anabolic response to 
intermittent PTH administration in mice, as PTH-induced mineral appositional rate, a 
measure of the work of osteoblast teams, is reduced in mice lacking Cx43 in osteoblastic 
cells [75]. On the other hand, deletion of Cx43 in osteocytes does not impair the ability of 
the hormone to increase bone mass, but PTH does not increase endocortical bone formation 
or mechanical properties in cortical bone of mice lacking osteocytic Cx43, suggesting that 
part of the effect of the hormone required the expression of Cx43 in osteocytes [119].
In vitro studies showed that Cx43 expression is required for the response of osteoblastic and 
osteocytic cells to mechanical stimulation [120]. Based on this finding, it was hypothesized 
that the response to mechanical loading is eliminated, or at least reduced, in the absence of 
Cx43 in osteoblasts and/or osteocytes. However, work of several groups showed that, 
instead, bone formation induced by mechanical loading is enhanced in mice in which Cx43 
was deleted from osteochondroprogenitors [80], from mature osteoblasts and osteocytes [78] 
or from osteocytes only [85]. This suggests that Cx43 restrains the response to loading likely 
through its function in osteocytes. It has been proposed that Cx43 sequesters β-catenin, 
thereby inhibiting Wnt signaling, known to increase bone formation [85]. Thus, in the 
absence of Cx43, β-catenin is free and Wnt signaling is increased. This primes osteoblastic 
cells to respond to mechanical signals by a yet to be identified mechanism. However, the 
detailed molecular pathway that mediates this inhibitory effect of Cx43 on bone formation 
induced by mechanical forces remains to be determined [120].
Osteoblastic Cx43 also participates in the response to lack of mechanical forces as 
demonstrated by reduced bone loss and a lack of increase in osteoclasts in mice lacking 
Cx43 in osteoblasts and osteocytes subjected to unloading by tail suspension compared to 
control mice expressing Cx43 [52,79]. In addition, absence of Cx43 in osteoblasts and 
osteocytes impairs fracture healing by a combination of decreased bone formation and bone 
resorption [121]. Interestingly, the effect of Cx43 deletion in fracture healing appears to be 
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opposite to that of normal bone, since the RANKL/OPG ratio is decreased, while the levels 
of the Wnt inhibitor sclerostin (i.e. the product of the Sost gene) are increased and β-catenin 
is decreased in the fracture [122]. In addition, the effect of Cx43 deletion on fracture healing 
can be reversed by increasing β-catenin stability [122]. These pieces of evidence raise the 
possibility that Cx43 has distinct roles in bone acquisition/maintenance versus bone healing.
Aging also affects Cx43 expression and function. Thus, osteoblastic cells from old rats (i.e. 
12-monhts old and 24/28-months old) exhibit decrease gap junction communication in 
response to PTH or cholera toxin, compared to cells from younger (i.e. 4-months old) 
animals [123]. On the other hand, no changes in Cx43 expression in osteoblastic cells 
isolated from young versus old rats were found. Similar results were shown in mice, with no 
change in mRNA levels for the gene when it was measured in vertebral bone from 6-months 
old and 24-months old mice [124]. However, in this case, PTH increased the levels of the 
Cx43 gene in both young and old mice. A more recent study showed that Cx43 protein 
expression is decreased in regenerated bone from aged (i.e. 21-months old) rats compared to 
mature (6-months old) animals, which is associated with reduced nitric oxide and 
prostaglandin E2 production following mechanical stimulation [125]. The old bones also 
exhibit decreased lacunar and osteocyte density. Whether the decrease in osteocyte viability 
and the accumulation of empty lacunae with old age results from decreased Cx43 protein 
expression or function remains to be determined.
Channel versus cytoplasmic domains: what we know about the function of 
Cx43 domains in bone cells?—Most of the studies in which the role of Cx43 in bone 
was investigated using genetic tools involved complete deletion of the molecule, precluding 
the possibility to understand the role of the different connexin domains in the overall 
phenotype [3]. Although the Cx43 variants associated with ODDD result from point 
mutations in particular amino acids, there is not always a direct relationship between the site 
of the mutation and the consequence in channel activity, ability to form gap junction 
channels versus hemichannels, or in the interaction and regulation of signaling molecules 
through the C-terminus domain [103].
A recent study described the skeletal phenotype of 2 mouse models with mutated Cx43 
expressed in osteocytes. In particular, in 1 model with the point mutation R67W, Cx43 has 
the ability to form functional hemichannels, but not gap junction channels, while in the other 
model, with a deletion of amino acids 130–136 (i.e. Δ130–136), Cx43 lacks channel 
permeability [126] and therefore cannot form either functional hemichannels or gap junction 
channels [127]. Mice expressing the Δ130–136 mutant exhibit increased bone mass, whereas 
R67W mice are undistinguishable from wild-type controls. No changes in cancellous bone 
was observed in either mice, but cortical bone was affected in Δ130–136 Cx43 animals, 
resulting in a phenotype that resembles that of mice with complete deletion of Cx43 from 
osteocytes [53,77]. Similarly, cortical osteocyte apoptosis was increased in mice expressing 
the mutated Δ130–136 Cx43 in osteocytes [127] as in mice lacking Cx43 in these cells [53]. 
On the other hand, Δ130–136 Cx43 animals, but not mice lacking Cx43 from osteocytes, 
display increased osteocyte apoptosis in cancellous bone. This discrepancy could be due to 
the purported low levels of Cx43 in cancellous bone, which could not be decreased further 
in mice lacking Cx43 in osteocytes. On the other hand, overexpression of Δ130–136 Cx43 
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might be toxic for osteocytes in this bone compartment. The expression of the anti-
osteoclastogenic cytokine OPG is decreased in Δ130–136 Cx43 mice as in mice with 
deletion of Cx43 in osteocytes. However, whereas the former also have reduced levels of the 
pro-osteoclastogenic cytokine RANKL, the animal model with complete deletion of Cx43 
exhibits high RANKL expression [3].
We recently analyzed the bone phenotype [119] of mice expressing a copy of a truncated 
form of Cx43 lacking the C-terminus tail (i.e. Cx43Δ245) in all cells and tissues [128]. Even 
though these mice still express a copy of the full length connexin, they exhibit decreased 
cancellous bone volume due to deficient osteoblast function, suggesting that truncated Cx43 
acts as a dominant negative, similar to the ODDD mutant [107]. This bone phenotype differs 
from the lack of effect of deleting Cx43 in mature osteoblasts and osteocytes [3] or of 
expressing channel-deficient Cx43 in osteocytes [127] in the cancellous bone compartment.
The current evidence for the role of the Cx43 domains in bone cells is shown in Table 1. 
Overall, Cx43-based channel function in osteocytes appears to be required for proper 
cortical bone acquisition and material strength, whereas the C-terminus domain is required 
to reach normal cancellous bone volume and osteoblast function. On the other hand, absence 
of channel activity increases bone mass and osteoblast function in cancellous bone, and the 
lack of the C-terminus domain results in increased cortical bone strength. In summary, Cx43 
domains exert distinct functions depending on the bone compartment study, controlling bone 
accrual and bone cell function and survival [53,119,127].
Cx37, a recently found bone connexin that regulates bone mass—In addition to 
Cx43, studies showed that Cx37 is also expressed in osteoblasts, osteocytes and osteoclasts 
[17,18]. Global deletion of Cx37 result in increased bone mass, an effect that is more 
pronounced in male than in female mice [17]. Consistent with this gender-specific effect of 
Cx37 deletion, men, but not women, carrying the Cx37-319P allele exhibit higher total 
body, lumbar spine, femoral neck and trochanter bone mineral density compared to 
individuals carrying the Cx37-319S allele in a Japanese population [129]. The murine high 
bone mass phenotype is due to decreased osteoclast differentiation, resulting in decreased 
osteoclast number and bone resorption without altering osteoblast differentiation or function 
[17].
4. Pannexins in bone
4.1. In vitro studies
Panx1 and 3 are expressed by osteoblasts [33], but their role is only beginning to be 
uncovered. Panx3 is a direct target of the osteoblastogenic transcription factor Runx2 and its 
expression increases during osteoblast differentiation [130]. Overexpression of Panx3 
promotes the osteogenic differentiation of C2C12 cells in culture, including inducing the 
expression of Sp7/Osterix and osteocalcin [37]. Conversely, short hairpin RNA-mediated 
knockdown of Panx3 inhibits osteoblastogenesis. In addition, ex vivo adenoviral 
transduction of newborn mouse metatarsals with a Panx3 expression construct enhanced 
osteoblastogenesis and increased bone length. Panx3 carries out this function by serving not 
only as a direct channel between the cytoplasm and extracellular space, but perhaps by also 
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acting as a calcium channel in the endoplasmic reticulum whose function converges on Akt 
signaling networks. Furthermore, Panx3-based channel activity can promote osteogenic 
differentiation through increased β-catenin activity and the attenuation of protein kinase A-
signaling permitting cell cycle exit and subsequent differentiation [38]. While it has been 
suggested that Panx3 may function as a gap junction-like channel for direct cell-to-cell 
communication [131], this is based on the use of relatively non-selective inhibitors that 
impact both gap junction and pannexin channel functions. Indeed, a recent paper has 
suggested that many of the hemichannel activities ascribed to Cx43 may be rather due to 
pannexin activities [132]. Panx1 is virtually unstudied in osteoblast or osteocytes and neither 
Panx1 nor 3 have been reported in osteoclasts.
4.2. In vivo studies
In vitro studies have shown that pannexins are involved in osteoblast differentiation and 
function as described above. However, in vivo evidence for the role of pannexins in bone 
cell biology is lacking. Even though mice with global deletion of Panx1 and 3 have been 
generated [133], their bone phenotype or lack thereof has not been reported. Nevertheless, a 
preliminary study presented as an abstract showed that the increase in RANKL, a cytokine 
required for osteoclast differentiation, which occurs in the area surrounding apoptotic 
osteocytes following microdamage is abolished in mice lacking Panx1 [134].
5. Connexins in cartilage, ligaments and tendons
5.1. In vitro studies
Cartilage—Cx43 is expressed in both articular chondrocytes as well as growth plate 
chondrocytes [135], but its role is quite intriguing, as these cells are generally functioning in 
virtual isolation free from many direct cell-to-cell contacts. While these cells can form 
classic gap junction in culture [19,136], it is generally thought that the role of Cx43 in 
chondrocytes may be related to hemichannel activity [137–140]. Cyclic loading of articular 
chondrocytes has been shown to open Cx43-based hemichannels and leads to the release of 
ATP, which may be part of a mechanotransduction pathway [137,138]. Furthermore, fluid 
flow shear stress has been shown to activate Cx43-based hemichannels in cultured 
chondrocytes, which in turn affects extracellular prostaglandin E2 levels [139], a model that 
closely mimics observations made in osteocytes [65,67]. Analogous to the role of Cx43 in 
osteoblasts, inhibition of Cx43 has been shown to restrict the differentiation of mesenchymal 
stem cells down the chondrogenic lineage, although in contrast to osteoblasts, this effect is 
independent on cell-to-cell contacts [140].
An interesting association has been made between Cx43 levels and osteoarthritis-related 
changes in the joint. In vitro, Cx43 is increased by the pro-inflammatory cytokine 
interleukin 1 in chondrocytes [141]. In synovial cells [141,142], Cx43 can increase calcium 
wave propagation between cells [136] and can as such influence signaling cascades and 
osteoarthritis-associated gene expression [143–145]. In vivo data implicating Cx43 in 
osteoarthritis pathology will be discussed below.
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Tendon—Tendon cells express Cx43 and Cx32, forming a 3-dimensional network in vivo 
[27]. In tenocytes exposed to mechanical load, Cx43 and Cx32 have opposing functions 
[29]. Cyclic tensile loading increases collagen secretion, an effect that is reduced by 
knockdown of Cx32 expression, but increased by knockdown of Cx43 expression. This may 
be consistent with a recent report showing downregulation of Cx43 protein expression 
following static tensile load [146]. However, loss of gap junctional coupling among 
tenocytes during aging has also been implicated in the reduced potential of specific tendons 
to repair [147]. Despite evidence that Cx43 inhibits tenocyte repair capacity, interleukin 1 
increases Cx43 expression in tenocytes, where it may play a role in cell survival following 
strain [148].
Ligament—Ligamentous fibroblasts express Cx43, Cx40, Cx45 and Cx32 [23–25]. As in 
the other skeletal tissues, it seems that mechanical strain opens Cx43-based hemichannels in 
ligament cells leading to the release of ATP [149]. In addition, an increase in Cx43 
expression is associated with pathologic mineralization of the posterior longitudinal 
ligament in the cervical spine [150]. Ligamentous cells isolated from patients with an 
ossified posterior longitudinal ligament have increased expression Cx43 and of osteogenic 
genes, including osteocalcin, alkaline phosphatase and collagen I, relative to control non-
ossified posterior longitudinal ligament cultures [150]. Furthermore, these changes in 
osteoblast gene expression can be inhibited by Cx43-targeting small interfering RNA. In 
addition, these ossified posterior longitudinal ligament cells have a more robust osteogenic 
response to mechanical strain, which depends on Cx43 expression [151]. Indeed, Cx43 
expression in ligament cells appears to be enhanced by mechanical strain [151,152]. Like in 
many other skeletal tissues, Cx43 influences ERK signaling in ligamentous fibroblasts and 
can regulate osteogenic genes during cyclic mechanical tension [153].
5.2. In vivo studies
Cartilage—Little is known about the role of connexins in cartilage in vivo. Cx43 is 
expressed by growth plate and articular chondrocytes [135] and chondrocytes in the 
meniscus [154] in vivo. Human chondrocytes also express Cx45, Cx32 and Cx46 [20]. 
Direct cell-to-cell communication has been shown in the superficial zone of articular 
chondrocytes [155]. A paradigm challenging study has even shown that chondrocytes in situ 
may form long cell processes, 5 to 150 microns in length, that permit communication 
through gap junction channels [156]. Increased presence of gap junction plaques and Cx43 
expression have been found in synovial lining cells obtained from the knee of patients with 
osteoarthritis [157]. Similarly, Cx43 production is increased in the cartilage of the knee and 
femoral head [20] and in the shoulders of patients with osteoarthritis, suggesting that the 
molecule might have a role in the pathogenesis of this disease [158]. Consistent with this, 
Cx43 levels in osteoarthritic cartilage correlate with the expression of several pro-
inflammatory and catabolic factors [158]. In line with this notion, silencing of Cx43 
expression protected against inflammation and joint destruction in a model of rheumatoid 
arthritis in rats [159].
Tendon—The expression of Cx43 and Cx32 has been studied in fetal and adult tendons 
obtained from horse [28], rat [27,160] and sheep [30]. These studies show that the 2 
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connexins are present throughout tendon development, although with a different pattern of 
expression and localization. Their level is high in fetal life and decreases in adult tissue, and 
these changes accompany the decrease in the proliferation index and cellularity of the 
tendons, as well as the change from round to elongated cell nuclei [27,28,30,160]. This 
suggests that Cx43 and Cx32 could be involved in the maturation of the tendon. However, 
further studies are required to confirm this possibility.
Ligaments—As for tendons, little is known on the role of connexins in ligaments in vivo. 
A study showed that Cx43 is increased in periodontal ligaments following experimental 
tooth movement [23]. Increases in Cx43 expression were found in spinal ligaments with 
ectopic bone formation [150]. Silencing Cx43 production inhibits the increase in 
osteoblastic genes after mechanical stimulation [151], suggesting that Cx43 plays a role in 
the progression of ectopic spinal ligament ossification.
6. Pannexins in cartilage, ligaments and tendons
6.1. In vitro studies
Beyond its expression in these tissues, very little is known about how pannexins can impact 
the function of these cells. Panx3 is both necessary and sufficient to induce chondrogenic 
differentiation of ATDC5 and primary chondrocytes in vitro [39]. Furthermore, Panx3 
expression in chondrocytic cells reduces intracellular cAMP levels, protein kinase A activity 
and diminishes the proliferative response to cAMP, suggesting that Panx3 regulates the 
switch from proliferation to chondrocyte differentiation [39].
In periodontal ligament cells, Panx1 interacts with P2X7 receptors as part of mechanical 
strain responsive mechanisms for ATP release [44]. Furthermore, this complex is involved 
in the secretion of interleukin 1β, perhaps through the regulation of vesicular secretion [44]. 
However, detailed molecular mechanisms still remain to be defined.
6.2. In vivo studies
To date, there are no reported studies in which pannexins were manipulated in cartilage, 
ligaments or tendons. Although studies with global deletion of pannexins do not report any 
gross abnormalities in these tissues, the possibility that pannexins are involved in the 
development or function of these tissues cannot be ruled out.
7. Conclusions
Extensive research has shown the fundamental role of Cx43 expression in osteoblast and 
osteocyte differentiation, intracellular signaling and in bone acquisition and maintenance, as 
well as in the response to stimuli that affect bone mass and strength. Furthermore, recent 
studies began to examine the domains of connexins that are responsible for their effect on 
bone, thereby uncovering a complex role of Cx43 and its cytoplasmic C-terminus and 
transmembrane channel domains depending on the bone envelope investigated. In addition 
to Cx43, recent studies show that Cx37 also is involved in bone homeostasis, yet in this case 
controlling osteoclast differentiation and bone resorption. On the other hand, little is known 
about the role of connexins in other skeletal tissue. Similarly, the role of pannexins in bone, 
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cartilage, tendon and ligaments is beginning to be revealed. Understanding the dynamics of 
cell-to-cell signaling via connexins and pannexins will enable the development of novel 
therapeutic strategies to optimize the musculoskeletal system and/or to enhance the 
effectiveness of current therapeutic agents by manipulating connexin and pannexin 
expression or activity.
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